Impact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration‐resistant Prostate Cancer
An interaction between BMI and hemoglobin was present in metastatic castration-resistant prostate cancer patients after docetaxel chemotherapy, explaining the observed survival difference between lean and overweight/obese patients. Comorbidities and medications had no significant impact on survival in this population with limited prognosis (median survival 16.1 months).
Authors
- Ellinor Haukland (ORCID: https://orcid.org/0000-0002-5697-2218)
- Carsten Nieder (ORCID: https://orcid.org/0000-0003-1592-2908)
- Luka Stanisavljević
- Astrid Dalhaug (ORCID: https://orcid.org/0000-0002-6542-6884)
Institutions
- Nordland Hospital Trust (NO)
- UiT The Arctic University of Norway (NO)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/cdp.10423
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00